Meaningful endpoints for therapies approved for hematologic malignancies
Author:
Affiliation:
1. Kimmel Cancer Center/Johns HopkinsBaltimore Maryland
2. GfK Market AccessSan Francisco California
3. Cedars‐Sinai Samuel Oschin Comprehensive Cancer InstituteLos Angeles California
Funder
Celgene
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30622
Reference25 articles.
1. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
2. End Points and United States Food and Drug Administration Approval of Oncology Drugs
3. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
4. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
5. What Are the Endpoints of Therapy for Acute Leukemias? Old Definitions and New Challenges
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS);European Journal of Cancer;2024-06
2. Real-World Outcomes of Adolescents and Young Adults with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Cohort Study;Journal of Adolescent and Young Adult Oncology;2023-10-16
3. Nanoengineered approaches to improve the efficacy of targeted drug delivery for the treatment of malignancy: a comprehensive review;Future Journal of Pharmaceutical Sciences;2023-10-16
4. Endpoint selection and evaluation in hematology studies;Best Practice & Research Clinical Haematology;2023-09
5. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial;Clinical Lymphoma Myeloma and Leukemia;2022-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3